Neurosense Therapeutics is trading 7.27% lower at $4.72, with no clear company-specific explanation identified for the September 29 decline.
- Latest company news is the CFO’s participation in a healthcare investor conference. The disclosed September 29 deadline to regain Nasdaq listing compliance is relevant background, not an established cause.
- The broader market was mixed, with all three major indexes down less than 0.6%; shares had dropped sharply on September 28 before the further live decline on September 29.